SuanFarma-Header SuanFarma-Header

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshReset Filter
              refresh Reset Filter
              price-trend All Drugs in Dev.

              Product Type

              Companies

              Dr. Reddy's Laboratories

              • Development Update

              Virtual BoothOffering a portfolio of products & services including APIs, CMO services, generics, biosimilars & differentiated formulations.

              Contact Supplier Contact Supplier
              Flag India
              Virtual Booth Virtual Booth

              CPhI Korea 2021

              Attending

              Request a Meeting Now

              Dr Reddy's Laboratories Launches Over-the-Counter Eye Allergy Drop, the Store-Brand E...

              Lead Product(s): Olopatadine Hydrochloride

              Therapeutic Area: Ophthalmology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 17, 2020

              Details:

              Dr. Reddy’s has launched of over-the-counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the storebrand equivalents of Pataday® Once Daily Relief and Pataday® Twice Daily Relief, in the U.S. market, as approved by the USFDA.

              Cipla

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              Post An Enquiry Post An Enquiry
              Flag India
              Virtual Booth Virtual Booth

              Mediterranean Congress of Chemical

              Participation Not Confirmed

              Update your events

              Cipla Receives Final Approval for Generic Version of Novartis Pharmaceuticals Corpora...

              Lead Product(s): Difluprednate

              Therapeutic Area: Ophthalmology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 12, 2021

              Details:

              Cipla’s Difluprednate Ophthalmic Emulsion 0.05% is AB-rated generic therapeutic equivalent version of Novartis Pharmaceutical Corporation’s Durezol®.

              Cipla